Phase II Trial of Topotecan, Carboplatin, and Paclitaxel as Front-Line Therapy in Suboptimal Advanced Epithelial Ovarian Cancer

By Bolis G.   Scarfone G.   Villa A.   Parazzini F.  

Gynecologic Oncology, Vol. 81, Iss. 2, 2001-05 ,pp. : 331-333

Elsevier

Access to resources Recommend Favorite

Identification of Risk Factors for Requiring Transfusion during Front-Line Chemotherapy for Ovarian Cancer

By Hensley M.L.   Lebeau D.   Leon L.F.   Venkatraman E.   Waltzman R.   Sabbatini P.   Almadrones L.   Chi D.   Spriggs D.  

Gynecologic Oncology, Vol. 81, Iss. 3, 2001-06 ,pp. : 485-489

Elsevier

Access to resources Recommend Favorite

Gemcitabine combined with cisplatin as first-line treatment in patients with epithelial ovarian cancer: a phase II study

By Belpomme D.   Krakowski I.   Beauduin M.   Petit T.   Canon J.L.   Janssens J.   Gauthier S.   De Pauw A.   Moreau V.   Kayitalire L.  

Gynecologic Oncology, Vol. 91, Iss. 1, 2003-10 ,pp. : 32-38

Elsevier

Access to resources Recommend Favorite

First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients

By Romanini A.   Tanganelli L.   Carnino F.   Fanucchi A.   Lionetto R.   Pastorino S.   Cosio S.   Gadducci A.   Conte P.F.  

Gynecologic Oncology, Vol. 89, Iss. 3, 2003-06 ,pp. : 354-359

Elsevier

Access to resources Recommend Favorite

A Phase 2 Study with Epirubicin as Second-Line Treatment of Patients with Advanced Epithelial Ovarian Cancer

By Havsteen H.   Bertelsen K.   Gadeberg C.C.   Jacobsen A.   Kamby C.   Sandberg E.   Sengelov L.  

Gynecologic Oncology, Vol. 63, Iss. 2, 1996-11 ,pp. : 210-215

Academic Press

Access to resources Recommend Favorite